Travel Medicine and Infectious Disease (Jul 2023)

Qdenga® - A promising dengue fever vaccine; can it be recommended to non-immune travelers?

  • Martin Angelin,
  • Jan Sjölin,
  • Fredrik Kahn,
  • Anna Ljunghill Hedberg,
  • Anja Rosdahl,
  • Paul Skorup,
  • Simon Werner,
  • Susanne Woxenius,
  • Helena H. Askling

Journal volume & issue
Vol. 54
p. 102598

Abstract

Read online

Qdenga® has been approved by the European Medicines Agency (EMA) for individuals > 4 years of age and for use according to national recommendations. The vaccine shows high efficacy against virologically confirmed dengue and severe dengue in clinical studies on 4–16-year old's living in endemic areas. For individuals 16–60 years old only serological data exists and there is no data for individuals > 60 years. Its use as a travel vaccine is still unclear. We present the studies behind the approval and the recommendations for travelers as issued by the Swedish Society for Infectious Diseases Physicians.